Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
DitchCarbon Score
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ortho Clinical Diagnostics's score of 33 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ortho Clinical Diagnostics's reported carbon emissions
In 2022, Ortho Clinical Diagnostics reported total carbon emissions of approximately 26,371,000 kg CO2e for Scope 1 and about 28,869,000 kg CO2e for Scope 2. This represents a significant increase in emissions compared to 2021, where Scope 1 emissions were about 17,320,000 kg CO2e and Scope 2 emissions were approximately 27,971,000 kg CO2e. The total emissions for Scope 1 and 2 combined in 2021 were around 45,291,000 kg CO2e, indicating a trend of rising emissions over the years. Ortho Clinical Diagnostics has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions to near zero by 2025. Additionally, the company plans to achieve a 30% reduction in Scope 1 GHG emissions from 2022 levels by 2030, as well as a similar 30% reduction target for Scope 2 emissions within the same timeframe. These targets reflect the company's commitment to addressing climate change and reducing its carbon footprint. The emissions data is cascaded from QuidelOrtho Corporation, the parent company, which provides a broader context for Ortho's sustainability efforts. As a current subsidiary of Ortho-Clinical Diagnostics, Inc., the company is actively working towards these reduction goals while navigating the challenges of increasing emissions in recent years.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 19,409,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 26,398,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ortho Clinical Diagnostics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
